Bausch Health Companies Inc. (TSX:BHC)
Canada · Delayed Price · Currency is CAD 7.89
-0.28 (-3.43%)
Aug 1, 2025, 4:00 PM EDT
Bausch Health Companies Employees
Bausch Health Companies had 20,700 employees as of December 31, 2024. The number of employees increased by 430 or 2.12% compared to the previous year.
Employees
20,700
Change (1Y)
430
Growth (1Y)
2.12%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
2.91B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20,700 | 430 | 2.12% |
| Dec 31, 2023 | 20,270 | 370 | 1.86% |
| Dec 31, 2022 | 19,900 | 300 | 1.53% |
| Dec 31, 2021 | 19,600 | -2,000 | -9.26% |
| Dec 31, 2020 | 21,600 | -100 | -0.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Green Thumb Industries | 4,800 |
| Sienna Senior Living | 12,263 |
| dentalcorp Holdings | 10,200 |
| Curaleaf Holdings | 5,519 |
| Trulieve Cannabis | 6,000 |
| WELL Health Technologies | 1,507 |
| Cronos Group | 459 |
| Extendicare | 23,000 |
Bausch Health Companies News
- 2 days ago - Bausch Health Companies Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 2 days ago - Bausch Health reaffirms 2025 revenue target of $4.95B–$5.1B as debt reduction and pipeline expansion advance - Seeking Alpha
- 2 days ago - Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Bausch Health Companies GAAP EPS of $0.40 beats by $0.36, revenue of $2.53B beats by $40M - Seeking Alpha
- 2 days ago - Bausch Health Announces Second Quarter 2025 Results - Accesswire
- 3 days ago - Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout - Benzinga
- 3 days ago - Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout - Benzinga
- 3 days ago - Bausch Health to acquire liver drug developer Durect for $1.75 per share - Seeking Alpha